{"title":"Ipilimumab plus nivolumab efficacious in patients with dMMR/MSI-H disease","authors":"Peter Sidaway","doi":"10.1038/s41571-024-00978-9","DOIUrl":null,"url":null,"abstract":"<p>The combination of the anti-PD-1 antibody nivolumab plus the anti-CTLA4 antibody ipilimumab showed promising efficacy outcomes as first-line therapy in 45 patients with mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) colorectal cancer (CRC) as part of the single-arm, phase II CheckMate 142 trial. Now, data from the phase III CheckMate 8HW trial confirm the efficacy of this combination in this setting.</p><p>A total of 303 patients who had not received systemic therapy for unresectable or metastatic dMMR/MSI-H CRC were randomly assigned (2:1) to receive either ipilimumab plus nivolumab or investigator’s choice of chemotherapy, with or without targeted therapy. Patients were also randomly assigned to a nivolumab monotherapy arm, although data from this arm were not reported at this cutoff. Progression-free survival (PFS) in those with centrally confirmed dMMR/MSI-H status (255 patients) was the primary end point.</p>","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"90 1","pages":""},"PeriodicalIF":81.1000,"publicationDate":"2024-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature Reviews Clinical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41571-024-00978-9","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
The combination of the anti-PD-1 antibody nivolumab plus the anti-CTLA4 antibody ipilimumab showed promising efficacy outcomes as first-line therapy in 45 patients with mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) colorectal cancer (CRC) as part of the single-arm, phase II CheckMate 142 trial. Now, data from the phase III CheckMate 8HW trial confirm the efficacy of this combination in this setting.
A total of 303 patients who had not received systemic therapy for unresectable or metastatic dMMR/MSI-H CRC were randomly assigned (2:1) to receive either ipilimumab plus nivolumab or investigator’s choice of chemotherapy, with or without targeted therapy. Patients were also randomly assigned to a nivolumab monotherapy arm, although data from this arm were not reported at this cutoff. Progression-free survival (PFS) in those with centrally confirmed dMMR/MSI-H status (255 patients) was the primary end point.
期刊介绍：
Nature Reviews publishes clinical content authored by internationally renowned clinical academics and researchers, catering to readers in the medical sciences at postgraduate levels and beyond. Although targeted at practicing doctors, researchers, and academics within specific specialties, the aim is to ensure accessibility for readers across various medical disciplines. The journal features in-depth Reviews offering authoritative and current information, contextualizing topics within the history and development of a field. Perspectives, News & Views articles, and the Research Highlights section provide topical discussions, opinions, and filtered primary research from diverse medical journals.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
